Experimental blood test shows promise in early pancreatic cancer detection

The short version

• Researchers evaluated a new blood test, PANXEON, in an early clinical trial involving approximately 1,800 people across the U.S., Europe, and Asia.[Scientific American]
• The test detected early-stage pancreatic cancers about 87 percent of the time with a low false-positive rate, using artificial intelligence to process three molecular signatures into a risk score.[Scientific American]
• Additional advanced clinical trials are required before the test can be approved for clinical use.[Scientific American]

Key facts

• The PANXEON test identified stage 1 and 2 pancreatic cancers with roughly 87 percent accuracy and a low false-positive rate.[Scientific American]
• The study evaluated the test on approximately 1,800 participants across the United States, Europe, and Asia.[Scientific American]
• The screening method evaluates three molecular signatures and applies artificial intelligence to calculate a cancer risk score.[Scientific American]
• PANXEON identified advanced pancreatic dysplasia over 64 percent of the time in individuals with high-risk pancreatic cysts.[Scientific American]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• Blood test shows promise in detecting pancreatic cancer early—a ‘holy grail’ for the fieldScientific American metered